CD68-ET3-LV CD34+gene therapy

N/A

Report date: 2024/07/11 17:20:23

Base Information

Drug NameCD68-ET3-LV CD34+gene therapy
Drug Alias NameHematopoietic stem cell transplantation (HSCT) gene therapyCD34+ hematopoietic stem cells transduced with CD68-ET3 lentiviral vector
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector
Mechanisms of ActionFactor VIII gene transference
TargetsCoagulation factor VIII
Therapy Area/IndicationsHemophilia A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIndia
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesExpression Therapeutics Llc
China Registration ClassN/A

Develop Information

Active CompaniesExpression Therapeutics LlcChristian Medical College, Vellore
Inactive CompaniesN/A
Active IndicationsHemophilia A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A